



## Appendix F: Ketamine Meta-analyses

Outcome and subgroup	Studies	Participants	I <sup>2</sup>	Risk Ratio (M-H, Fixed, 95% CI)	Risk Ratio (M-H, Random, 95% CI)
1.1 Prevalence of any pain at 3 mo., drug ≤24h, mixed surgical procedures	4	298	0	0.94 [0.70, 1.28]	1.01 [0.77, 1.32]
1.2 Prevalence of any pain at 3 mo., drug >24h, mixed surgical procedures	5	331	24	0.83 [0.58, 1.18]	0.82 [0.54, 1.25]
1.3 Prevalence of moderate/severe pain at 3 mo., drug >24h, mixed surgical procedures	2	128	0	0.51 [0.16, 1.58]	0.52 [0.16, 1.64]
1.4 Prevalence of any pain at 6 mo., drug ≤24h, mixed surgical procedures	6	553	57	<b>0.74 [0.61, 0.91]</b>	0.62 [0.36, 1.07]
1.5 Prevalence of any pain at 6 mo., drug >24h, mixed surgical procedures	10	591	0	0.91 [0.74, 1.12]	0.91 [0.75, 1.11]
1.6 Prevalence of moderate/severe pain at 6 mo., drug >24h, mixed surgical procedures	5	284	0	0.68 [0.40, 1.17]	0.68 [0.39, 1.17]
1.7 Prevalence of any pain at 12 mo., drug ≤24h, mixed surgical procedures	3	244	0	0.48 [0.16, 1.49]	0.51 [0.14, 1.92]
1.8 Prevalence of any pain at 12 mo., drug >24h, mixed surgical procedures	2	103	0	0.82 [0.42, 1.61]	0.83 [0.42, 1.62]
1.9 Prevalence of moderate/severe pain at 12 mo., drug >24h, mixed surgical procedures	2	103	0	0.40 [0.12, 1.27]	0.42 [0.13, 1.34]
1.10 Prevalence of any pain at 6 mo., abdominal/pelvic surgery	2	164	31	<b>0.40 [0.19, 0.88]</b>	0.37 [0.12, 1.11]
1.11 Prevalence of any pain at 3 mo., thoracotomy	4	240	42	0.85 [0.59, 1.22]	0.84 [0.52, 1.38]
1.12 Prevalence of moderate/severe pain at 3 mo., thoracotomy	2	128	0	0.51 [0.16, 1.58]	0.52 [0.16, 1.64]
1.13 Prevalence of any pain at 6 mo., thoracotomy	5	310	43	0.92 [0.67, 1.26]	0.90 [0.56, 1.44]
1.14 Prevalence of moderate/severe pain at 6 mo., thoracotomy	2	120	0	1.01 [0.18, 5.69]	0.95 [0.14, 6.29]
1.15 Prevalence of any pain at 6 mo., total knee arthroplasty	2	59	0	0.84 [0.60, 1.17]	0.87 [0.63, 1.20]


### Analysis 1.1. Ketamine versus placebo comparisons, prevalence of any pain at 3 months (drug administration ≤ 24 hours)




**Analysis 1.2. Ketamine versus placebo comparisons, prevalence of any pain at 3 months (drug administration > 24 hours)**




**Analysis 1.3. Ketamine versus placebo comparisons, prevalence of moderate/severe pain at 3 months (drug administration > 24 hours)**




### Analysis 1.4. Ketamine versus placebo comparisons, prevalence of any pain at 6 months (drug administration ≤ 24 hours)




## Analysis 1.5. Ketamine versus placebo comparisons, prevalence of any pain at 6 months (drug administration > 24 hours)



### Analysis 1.6. Ketamine versus placebo comparisons, prevalence of moderate/severe pain at 6 months (drug administration > 24 hours)




**Analysis 1.7. Ketamine versus placebo comparisons, prevalence of any pain at 12 months (drug administration ≤ 24 hours)**







**Analysis 1.8. Ketamine versus placebo comparisons, prevalence of any pain at 12 months (drug administration > 24 hours)**




**Analysis 1.9. Ketamine versus placebo comparisons, prevalence of moderate/severe pain at 12 months (drug administration > 24 hours)**




**Analysis 1.10. Ketamine versus placebo comparisons, prevalence of any pain at 6 months (abdominal and/or pelvic surgery)**




**Analysis 1.11. Ketamine versus placebo comparisons, prevalence of any pain at 3 months (thoracotomy)**




**Analysis 1.12. Ketamine versus placebo comparisons, prevalence of moderate/severe pain at 3 months (thoracotomy)**



**Analysis 1.13. Ketamine versus placebo comparisons, prevalence of any pain at 6 months (thoracotomy)**



**Analysis 1.14. Ketamine versus placebo comparisons, prevalence of moderate/severe pain at 6 months (thoracotomy)**



**Analysis 1.15. Ketamine versus placebo comparisons, prevalence of any pain at 6 months (total knee arthroplasty)**

